Kindeva Drug Delivery L.P.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kindeva Drug Delivery L.P. - overview
Established
2020
Location
-, MN, US
Primary Industry
Medical Devices & Equipment
About
Kindeva Drug Delivery L. P. specializes in contract development and manufacturing of advanced drug-device combination products, focusing on innovative delivery systems for pharmaceuticals. Kindeva Drug Delivery L.
P. is a Contract Development and Manufacturing Organization (CDMO) established in 2020 in the United States. The company has undergone a strategic shift with a merger involving Meridian Medical Technologies, Inc. in November 2022, which supports its goal to enhance drug-device combination product offerings.
Kindeva is headquartered in the US and is led by CEO Aaron Mann. The company has raised a total of USD 650. 00 mn, with its latest funding round, a Corporate Carve Out, successfully completed in November 2022, involving investors from Altaris. Kindeva is a CDMO that specializes in drug-device combination products, offering pressurized metered-dose inhalers (pMDIs), autoinjectors, drug-in-adhesive patches, and microneedle array patches.
The company focuses on improving drug delivery technologies, having developed the first commercially available dose counter for inhalers and low global warming potential (GWP) inhalers, ultimately enhancing patient compliance and safety across various therapeutic areas, including respiratory diseases and vaccinations. Kindeva serves a diverse global clientele, primarily in North America, Europe, and Asia. In 2018, Kindeva reported a revenue of USD 380,000,000, primarily driven by B2B partnerships with pharmaceutical companies and healthcare organizations for the development and manufacturing of drug delivery systems. Their revenue model is based on contractual agreements that outline development fees, manufacturing costs, and royalties linked to product sales, ensuring a structured pricing plan that evolves alongside client needs.
Kindeva Drug Delivery L. P. aims to leverage its recent merger to advance its capabilities as a drug-device combination product CDMO. The company is focused on creating new products and expanding into new geographic regions.
Specific plans include increasing its presence in emerging markets within Asia and Europe by 2024. The recent funding from the USD 650. 00 mn Corporate Carve Out will be utilized to support these initiatives, enhancing product development and market entry strategies.
Current Investors
Kindeva Drug Delivery L.P.
Primary Industry
Medical Devices & Equipment
Sub Industries
Therapeutic Devices, Medical Equipment Distributors, Packaging
Website
www.kindevadd.com
Verticals
Manufacturing
Company Stage
Merged
Total Amount Raised
Subscriber access only
Kindeva Drug Delivery L.P. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | Kindeva Drug Delivery L.P., Meridian Medical Technologies, Inc. | - | ||||||||
| Add-on | Completed | iPharma Labs Inc. | - | ||||||||
| Corporate Carve Out | Completed | Kindeva Drug Delivery L.P. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.